Omega-3 (EPA/DHA)

Omega-3 has the strongest longevity evidence of any commonly consumed supplement, if you accept a broad definition of longevity that includes cardiovascular disease, cognitive decline, and inflammation. The evidence is not from small aging biomarker studies. It is from million-person cohort studies of blood Omega-3 Index (the percentage of EPA+DHA in red blood cell membranes) predicting all-cause mortality.

The Omega-3 Index is one of the strongest single-value blood test predictors of premature death in existence. In the Framingham Heart Study, those in the highest quintile (over 6.8%) had a 34% lower risk of death from any cause and 39% lower risk of incident cardiovascular disease compared to the lowest quintile (under 4.2%) [1]. The Omega-3 Index outperformed serum cholesterol as a mortality predictor in the same model. A practical target is 8% or higher, achievable for most people with 1,300 mg/day of EPA+DHA over 4 months.

Randomized trial evidence is more mixed. The REDUCE-IT trial found high-dose EPA (icosapent ethyl, prescription, 4 g/day) reduced cardiovascular events by 25% in statin-treated patients with elevated triglycerides [2]. The STRENGTH trial with EPA+DHA carboxylic acid at 4 g/day did not show benefit and was stopped early for futility [3]. A secondary analysis found no benefit even in patients reaching the highest EPA blood levels, leading the authors to suggest the REDUCE-IT result may be partly explained by the mineral oil placebo causing harm [4]. The VITAL trial with 1 g/day of EPA+DHA showed no significant reduction in major cardiovascular events but a 28% reduction in myocardial infarction [5]. The prescription forms tend to outperform supplement forms, which speaks to dose and purity.

High-EPA fish oil (cardiovascular)

The REDUCE-IT trial (Bhatt 2019, NEJM) randomized 8,179 statin-treated patients with elevated triglycerides to 4 g/day of icosapent ethyl (purified EPA ethyl ester) or mineral oil placebo. Over 4.9 years, the EPA group had 25% fewer primary cardiovascular events (HR 0.75, 95% CI 0.68-0.83) and 20% fewer cardiovascular deaths [2]. This is the single strongest RCT evidence for omega-3 cardiovascular benefit.

The STRENGTH trial (Nicholls 2020, JAMA) tested 4 g/day of EPA+DHA carboxylic acid (Epanova) vs corn oil in 13,708 patients. The primary endpoint HR was 0.99 (no benefit) and the trial was stopped early [3]. A secondary analysis (JAMA Cardiology 2021) found no benefit even in the top tertile of EPA blood levels [4]. The contrast between REDUCE-IT and STRENGTH raises two explanations: pure EPA may work better than EPA+DHA combined, or the mineral oil placebo in REDUCE-IT inflated the apparent benefit by raising LDL cholesterol in the control group.

Both trials found increased atrial fibrillation with omega-3 treatment, a consistent safety signal across high-dose omega-3 RCTs.

Practical guidance: For cardiovascular risk reduction, prescription icosapent ethyl (Vascepa) at 4 g/day has the strongest RCT backing. Over-the-counter fish oil at 1 g/day has weak evidence (VITAL). Doses of 2-3 g/day EPA+DHA target the Omega-3 Index rather than direct cardiovascular event reduction.

DHA-forward algae oil (cognitive, vegan)

Algae are the original source of DHA in the marine food chain. Fish accumulate DHA by eating algae, not by synthesizing it. Fermentation-grown Schizochytrium sp. microalgae produce DHA and EPA directly, without marine harvesting [6].

ALA (flax, chia, walnut) converts to EPA and DHA at very low rates in humans: 1-10% for EPA and under 5% for DHA [7]. Some studies report conversion as low as 0.2% for EPA and 0.05% for DHA. This means flaxseed oil is not a substitute for marine or algal omega-3.

Algal DHA from Schizochytrium sp. is bioavailable at doses as low as 250 mg/day, doubling serum DHA in vegans over 4 weeks [6]. A 2025 trial confirmed algal DHA/EPA is statistically non-inferior to fish oil in bioavailability [15]. The dominant commercial algal oil ingredient is life'sOMEGA (DSM), used in Performance Lab, Ovega-3, and other vegan brands.

DHA concentrates in brain and retinal tissue. Observational data links higher DHA intake to slower cognitive decline, though RCT evidence for cognitive benefit in healthy adults remains modest. DHA-forward products (higher DHA than EPA) are commonly marketed for brain and eye health.

Practical guidance: Vegans and vegetarians should supplement with at least 250 mg/day of algal DHA. Algal oil is bioequivalent to fish-derived DHA. Cost per gram is higher than fish oil, but contamination risk (heavy metals, PCBs) is lower because algae are grown in controlled fermentation tanks.

Krill oil (phospholipid delivery)

Krill oil delivers EPA and DHA bound to phospholipids rather than triglycerides. The phospholipid form is claimed to have higher bioavailability. A 2015 crossover trial in 15 healthy subjects found krill oil had a higher 72-hour bioavailability (iAUC 89.08%) than fish oil (59.15%, p=0.003) [8]. A 2024 meta-analysis of 26 studies confirmed superior absorption at doses under 2,000 mg, but noted that high-dose fish oil (over 3,000 mg) was more effective for raising the Omega-3 Index [9].

However, the same crossover trial found that krill meal and fish oil had similar bioavailability, which argues against the phospholipid superiority hypothesis [8]. The evidence is suggestive but not conclusive.

Krill oil contains naturally occurring astaxanthin, a carotenoid antioxidant that helps prevent oxidation of the oil. This is a genuine advantage over unprotected fish oil products. Krill oil also provides choline.

The Antarctic krill fishery is MSC certified. The IKOS (International Krill Oil Standards) certification program exists but few brands carry it. A 2024 RCT of 2g/day krill oil for 24 weeks in 262 adults found no significant improvement in knee osteoarthritis pain versus placebo [16]. Most krill oil products have low total EPA+DHA per serving (74-250 mg), meaning you need multiple softgels to reach therapeutic doses.

Practical guidance: Krill oil may offer better absorption at lower doses, but total omega-3 per serving is typically far below fish oil alternatives. For therapeutic dosing (1,000+ mg EPA+DHA), fish oil is more cost-effective. Krill oil is a reasonable choice for maintenance dosing (250-500 mg/day) or for people who experience fishy aftertaste with fish oil.

Cod liver oil (natural vitamins A and D)

Cod liver oil is a traditional supplement that provides omega-3 alongside naturally occurring vitamins A and D. Historic use of cod liver oil for rickets prevention dates back over a century.

Unrefined cod liver oil (e.g., Rosita EVCLO) retains natural vitamins A and D in their native forms. Refined cod liver oil, produced by molecular distillation, strips out most natural vitamins; manufacturers then add back synthetic vitamin A and D [10]. This matters because the A:D ratio in unrefined oil is naturally balanced, while refined products may have disproportionate ratios.

Vitamin A toxicity is a concern at high doses. The tolerable upper intake level is 3,000 mcg RAE (10,000 IU) per day for adults. Most cod liver oil products provide 1,000-5,000 IU vitamin A per serving, well below the upper limit at recommended doses. However, some fermented cod liver oils contain higher levels (up to 12,500 IU per teaspoon) [10]. Pregnant women should be particularly cautious with vitamin A intake.

Practical guidance: If using cod liver oil as an omega-3 source, be aware of the vitamin A and D content. Unrefined products (Rosita EVCLO) preserve the natural vitamin profile but lack standardized EPA/DHA levels. Refined products offer standardized omega-3 but may contain synthetic vitamins. Cod liver oil is not the most cost-effective way to get high-dose EPA+DHA alone.

Fish oil oxidation (TOTOX and freshness)

Oxidation is the primary quality concern in fish oil supplements. Oxidized fish oil may be pro-inflammatory and provide less benefit than fresh oil. The TOTOX value (2 x peroxide value + anisidine value) measures total oxidation. The GOED voluntary standard sets limits at peroxide under 5 mEq/kg, anisidine under 20, and TOTOX under 26. IFOS uses a stricter TOTOX limit of 19.5.

A study of 171 fish oil supplements found that 50% exceeded voluntary limits for at least one oxidation measure, and 39% exceeded TOTOX limits [11]. A New Zealand survey of 32 products found 83% exceeded peroxide limits and only 3 of 32 met labeled EPA+DHA content [13]. A separate analysis of 72 omega-3 supplements found that 68% of flavored and 13% of unflavored products exceeded the GOED TOTOX limit [12]. Flavored products may mask rancidity, making secondary oxidation harder to detect.

The biological effects of consuming oxidized fish oil are not fully established. EFSA concluded in 2010 that information on oxidation levels and related toxicological effects in humans is lacking [11]. However, a human RCT (Br J Nutr) giving 8g/day of oxidized fish oil (PV 18 mEq/kg) for 3-7 weeks found no significant change in oxidative stress or inflammatory markers in healthy subjects [14], suggesting short-term oxidized oil may not cause acute harm, though it likely reduces potency.

Practical guidance: Look for products with published IFOS batch reports showing TOTOX under 19.5. The lowest TOTOX values in our catalog are Wiley's Finest Peak Omega-3 (3.4), Sports Research Triple Strength (5.85), Puori O3 (6.86), and OmegaVia Ultra Concentrated (7.72). Liquid fish oil should be refrigerated after opening. Avoid products in clear plastic bottles. Choose products with natural antioxidants (mixed tocopherols, rosemary extract) added for freshness.

Source comparison: krill vs fish oil

Three head-to-head RCTs disagree on whether krill oil is better absorbed than fish oil. A 2026 trial (n=72) found krill produced a 1.5-fold higher increase in plasma EPA and DHA than fish oil at 12 weeks (AJCN 2026). Ulven et al. found krill raised the omega-3 index more than fish oil (P=0.0143) in a 4-week crossover (Lipids Health Dis 2013). But a rigorous 12-week German trial (n=62) found equal bioavailability: krill omega-3 index rose 1.15 percentage points vs fish oil 1.00 points, not statistically different (Lipids 2023). On lipid endpoints, a meta-analysis of 7 RCTs (662 participants) found krill oil lowers LDL by -15.52 mg/dL and triglycerides by -14.03 mg/dL (Nutrition Reviews 2017). No trial reports hard cardiovascular event data for krill vs fish oil. Krill is not proven superior; the practical difference for most users is small.

Source comparison: fish species and EPA:DHA ratios

Species differ enormously in EPA+DHA content and ratio. Per 100g: Atlantic mackerel supplies 2,500mg EPA+DHA (1:1.8 ratio), Pacific herring 1,700mg (1:0.7, EPA-dominant), farmed Atlantic salmon 1,800mg (1:2.0), and canned sardines 1,000mg (1:1.5) (OSU Seafood Composition). Tuna is markedly DHA-skewed (albacore 1:3.3, bluefin 1:3.0). For triglyceride lowering, EPA-heavier fish like herring or mackerel may be preferable. For prenatal DHA needs, tuna or salmon supply more DHA per gram. The chemical storage form does not vary by species: across all sampled species, more than 90% of fish DHA sits in triacylglycerols (Marine Drugs 2025). Oily cold-water species (mackerel, herring, salmon, sardine, anchovy) reliably outrank lean whitefish (cod, tilapia, pollock) by 3- to 10-fold on total EPA+DHA (NIH ODS).

Source comparison: farmed vs wild fish

Two things are simultaneously true. First, omega-3 concentration in farmed salmon has fallen roughly 50% from 2006 to mid-2010s as feed shifted from marine fish oil to vegetable oils: a 130g portion supplied 3.5g EPA+DHA in 2006, declining to about 1.5g per 100g (Scientific Reports 2016). Second, farmed salmon is not automatically lower than wild on a per-portion basis today: farmed fish carry more total fat, so a 200g portion can deliver 3.2g EPA+DHA vs 2.8g for wild (Environmental Research 2017). The tradeoff is a worse omega-3:omega-6 ratio in farmed fish due to vegetable-oil feed. Farmed salmon remains a strong omega-3 source, just with a less favorable fatty-acid profile and a documented downward trend in concentration.

Source comparison: algae vs fish oil

Algal DHA is bioequivalent to fish-derived DHA. A randomized trial giving 600mg DHA from algal capsules vs 600mg from cooked salmon produced statistically indistinguishable plasma and erythrocyte DHA increases in 32 adults (JADA 2008). Dose-response is linear across 200-1,000mg/day (Lipids 2007). The key asymmetry is EPA: most commercial algal oil is DHA-dominant because the workhorse species (Schizochytrium) makes little EPA. Contamination risk is structurally lower for algae because it is not filtered through a marine food web. For DHA specifically, algae is a proven equivalent to fish. For EPA, check the label.

Source comparison: cod liver oil dosing ceiling

Cod liver oil delivers the same EPA and DHA molecules as fish body oil, but carries vitamin A alongside them. Health Canada caps daily cod liver oil dose by the vitamin A tolerable upper limit (roughly 3,000 mcg RAE/day for adults), not by omega-3 content (Health Canada NHP Monograph). Someone targeting 2-4g/day EPA+DHA may not reach that dose safely with cod liver oil alone without risking vitamin A excess. Fish body oil has no equivalent dosing ceiling. Cod liver oil is fine at label doses but is not a substitute for dose-titratable omega-3 therapy.

Source comparison: small fish vs large predators (contaminants)

Mercury biomagnifies up the food chain. The FDA/EPA joint advisory classifies anchovy, herring, sardine, and mackerel as "Best Choice" (lowest mercury), while albacore and yellowfin tuna are "Good Choice" (eat less often), and king mackerel, shark, swordfish, and bigeye tuna are "Choice to Avoid" (FDA Advice About Eating Fish). Small, short-lived forage fish carry less mercury because they have not lived long enough to accumulate it. They are also more sustainable: they reproduce faster and support larger catch volumes (MSC Small Pelagic Fish). Small oily fish are nutritionally competitive with or superior to tuna on raw EPA+DHA per 100g.

Source comparison: molecular form (EE vs TG vs rTG)

Molecular form has a measured effect on absorption. Free fatty acid form absorbs at greater than 95%. Natural triglyceride (TG) form absorbs at 57-68% relative to free fatty acids. Ethyl ester (EE) form absorbs distinctly worse at 40-48%, unless taken with a fatty meal (BBRC 1988). Re-esterified triglyceride (rTG) products aim to recover TG-level absorption after EE concentration, but commercial rTG products range from under 70% to over 95% actually re-esterified. A 16-week RCT found higher-purity rTG produced significantly better erythrocyte EPA and DHA incorporation than lower-purity rTG (PLOS ONE 2023). If a label says "omega-3 concentrate" without specifying form, assume ethyl ester. Look for "triglyceride" or "rTG" on the label for better absorption.

Source comparison: eating fish vs supplements

The YouFish Study (RCT, n=40) directly compared fish consumption against supplementation. Two fish portions per week raised the omega-3 index by +2.27 percentage points over 8 weeks. A daily 700mg EPA+DHA capsule raised it by +2.03 percentage points, nearly the same magnitude (Journal of Nutrition 2025). This matches earlier data showing salmon-derived and capsule-derived DHA raise blood levels identically at matched doses. The practical difference is not absorption but dose reliability: fish meals bring protein, vitamin D, and selenium that capsules do not, while capsules bring dose consistency and easier titration. Neither route has a demonstrated absorption advantage.

Omega-3 integrity: MSC certification crisis for Antarctic krill

The MSC certification for Antarctic krill (Euphausia superba) harvested by The QRILL Company (Aker BioMarine subsidiary) has been formally paused since March 2026. WWF and the Antarctic and Southern Ocean Coalition (ASOC) filed objections on March 1-2, 2026 against a preliminary 300-page recertification report. Under MSC rules, certification cannot proceed until the objection process is resolved, and no timeline has been publicly specified (j-fish.com, The Guardian, March 2026). WWF, a founding partner of MSC, has called for an immediate moratorium on krill fishing (WWF UK, March 2026). Holland & Barrett, one of Europe's largest health retailers, ended all krill product sales by April 2026 (Sea Shepherd, March 2026). For consumers, an MSC label on a krill product cannot currently be treated as a stable, verified sustainability signal. Products from Olympic Seafoods' separate fishery are not affected by this specific dispute.

GOED freshness and contaminant thresholds

The Global Organization for EPA and DHA Omega-3s (GOED) Voluntary Monograph (v8.1) sets the reference standards for omega-3 oil quality. Oxidation limits: peroxide value (PV) max 5 meq/kg, p-anisidine value (pAV) max 20, TOTOX max 26 (calculated as 2xPV + pAV). Contaminant limits: PCB max 0.09 mg/kg, dioxins max 1.75 pg WHO-PCDD/F-TEQ/g, lead max 0.05 mg/kg (reduced from 0.1 mg/kg in late 2025), cadmium max 0.1 mg/kg, mercury max 0.1 mg/kg, inorganic arsenic max 0.1 mg/kg (GOED Monograph, EPAX announcement, December 2025). Independent testing finds 30-50% of commercial omega-3 products exceed GOED thresholds, making third-party testing essential rather than optional. TOTOX bands used by the industry: under 10 is excellent freshness, 10-15 is premium, 15-26 is GOED-compliant but not optimal for long-term use, and over 26 indicates significant oxidation with reduced efficacy.

Verification technologies: Raman spectroscopy and NMR

Portable Raman spectroscopy combined with machine learning (interpretable one-class SVM, or iSVM) can distinguish certified from non-certified omega-3 fish oil capsules with 96% accuracy (internal validation) and 92% accuracy (external validation). The model was trained on 248 certified and 520 uncertified samples and identifies spectral differences in unsaturated fat band regions (Food Control, December 2024). Separately, 1H NMR-based multivariate analysis can classify fish oil supplements by lipid type (triglyceride vs ethyl ester vs other forms) through PLS-DA and OPLS-DA discriminant models. This means molecular form claims (TG, rTG, EE, PL) can in principle be verified spectroscopically rather than relying solely on manufacturer label statements. These technologies open the possibility of future in-store or platform-level verification without sending samples to external labs.

How NO1GEVITY validates omega-3 claims

Every omega-3 product page on this site now carries a verification layer: three badges that tell you exactly what we checked, how many independent source types confirm each fact, and when we last verified it. The verification layer is separate from the overall score. A product can score well on price and dose and still carry a "claim only" stamp for its batch quality, meaning no independent lab report exists.

The three verification dimensions are:

1. Source trace. We verify the fish species, fishing ground, wild or farmed status, and named sustainability certification (MSC, FOS, Friend of the Sea) against manufacturer pages and certification body registries. If the manufacturer does not disclose the species or region, the badge reads "Manufacturer claim only." If the certification is under active dispute, as is the case for Antarctic krill MSC in 2026, the badge reads "Source checked, certification disputed."

2. Batch quality. We look for a published IFOS or Nutrasource batch report that independently confirms EPA and DHA content, TOTOX oxidation value, and contaminant levels (mercury, lead, arsenic, PCBs, dioxins). When a batch report exists, the badge reads "Batch lab-validated." When no public batch report exists, it reads "No public batch report." The TOTOX band classification (excellent under 10, premium 10-15, GOED-compliant 15-26) comes directly from these batch reports.

3. Consumer signal. We aggregate public consumer discussions across forums, review platforms, and marketplace reviews. When the same tolerability, complaint, or praise pattern appears across multiple independent consumer sources, the badge reads "Repeated consumer theme." When public discussion is thin or limited to a single platform, it reads "Thin consumer signal." Consumer signals are not validated facts. They are recurring themes.

Each verification badge carries a review date and a refresh-due date. Batch quality data is refreshed every 6 months or when a new batch is published. Consumer sentiment is refreshed every 6 months. Certification disputes like the MSC krill objection are checked every 90 days. General research findings are refreshed every 12 months. When the refresh-due date passes, the badge does not disappear, but a reader can see the data may be stale.

The verification layer is additive. It does not change the overall score, the evidence grade, or the ranking. Its purpose is to make the trust level of each individual claim visible and auditable 8.

Omega-3 as a periodontal adjunct (2026 update)

A 2026 meta-analysis pooled 15 randomized trials with 617 participants testing omega-3 added to scaling and root planing. Probing pocket depth improved by 0.43 mm on average (95% CI 0.18 to 0.68), clinical attachment level by 0.47 mm 1. Heterogeneity was high (I-squared 92%) and GRADE certainty was very low to low. The pooled conclusion: a supportive adjunct, not a substitute for mechanical periodontal treatment 1. A separate 12-week pilot in 57 youth with migraine is a reminder of why outcomes matter: the omega-3 index rose by 1.64 points (p<0.001) while no patient-reported outcome improved 2.

Products with this: Omega-3 (EPA/DHA)